- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Laura Long Says Pathways Are Part of a Bigger Care Delivery Transformation
Historically, people talk about pathways as if they are an answer, but they are really just one component to cancer care delivery, said Laura Long, MD, MPH, president at TheLongView, PC.
Historically, people talk about pathways as if they are an answer, but they are really just one component to cancer care delivery, said Laura Long, MD, MPH, president at TheLongView, PC, and editorial board member for The American Journal of Pharmacy Benefits.
"What [pathways] can do is help reduce variation and help improve the delivery of evidence-based care, but you need to have the rest of the package," she said.
Payment still needs to be aligned with outcomes and the care delivery model needs to become more patient-centered, Dr Long added.
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
